After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Pacira BioSciences Inc. (PCRX) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $42.05. The Pacira BioSciences Inc. has recorded 169,516 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $42.05 and fluctuated between $42.80 as its day high and $40.99 as its day low. The current market capitalization of Pacira BioSciences Inc. is $1.94B. A total of 0.6 million shares were traded on the day, compared to an average of 584.56K shares.
Insider Activity
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, PCRX has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 704 shares. Over the last 12 months, there were 36 BUYs and 49 SELLs from insiders. Insiders purchased 268,073 shares during that period but sold 160,009.
In the most recent transaction, MOLLOY ANTHONY sold 546 shares of PCRX for 38.31 per share on Jan 05. After the transaction, the Chief Lgl & Compliance Officer now owns 19,450 company shares. In a previous transaction on Jan 04, MOLLOY ANTHONY sold 158 shares at 39.09 per share. PCRX shares that Chief Lgl & Compliance Officer owns now total 19,996.
Among the insiders who sold shares, REINHARDT MAX disposed of 1,380 shares on Oct 07 at a per-share price of $58.00. This resulted in the President, Rest of World holding 31,378 shares of PCRX after the transaction. In another insider transaction, WINSTON ROY sold 476 shares at $55.70 per share on Aug 03. Company shares held by the Chief Medical Officer now total 44,992.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for PCRX in the last 3 months, the mean price target is $62.60 with high estimates of $80.00 and low estimates of $50.00. In terms of 52-week highs and lows, PCRX has a high of $82.16 and a low of $35.35.
As of this writing, PCRX has an earnings estimate of $0.87 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of $1.03 per share and a lower estimate of $0.7. The company reported an EPS of $0.51 in the last quarter, which was -40.00% lower than expectations of $0.85.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCRX is Hold with a score of 4.40. A total of 7 analysts rated the stock as Buy while 1 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.
